Introduction
============

Atherosclerosis with its associated cardiovascular events, myocardial infarction (MI), sudden cardiac death or stroke, is one of the leading causes of death in the western countries ([@b72]). Inflammation and lipid peroxidation, as well as chronic activation of the renin-angiotensin system (RAS), are hallmarks of atherogenesis. Activated RAS, inflammatory processes and lipid peroxidaton products contribute to the initiation, progression and rupture of atherosclerotic plaques ([@b61]; [@b48]; [@b84]). Therefore reducing pro-inflammatory mediators, and inhibiting the modulation of their releasing pathways, may be important both for the stability of atherosclerotic lesions and the perpetuation of atherosclerotic plaques ([@b83]).

In addition to this link, more direct interactions have been suggested between a chronically activated RAS, and elevated pro-inflammatory cytokines and lipoproteins, which may also promote atherogenesis ([@b62]). An increasing amount of evidence indicates that secretory phospholipase A~2~ (sPLA~2~) enzymes present in the vessel wall have localized effects that promote these processes ([@b39]; [@b30]; [@b63]; [@b86]; [@b56]). Three members (group IIA, group V and group X) of the various sPLA~2~ isozymes have been detected in murine or human atherosclerotic lesions ([@b59]; [@b71]; [@b91]); expression and localization of secretory phospholipase A~2~ group IIA (sPLA~2~-IIA) in human atherosclerotic tissue have been the best documented until now ([@b79]; [@b40]; [@b32]). In this context, recent investigations have suggested the involvement of sPLA~2~-IIA as part of a systemic and localized acute-phase-reaction in the development of atherosclerosis, not only as a specific marker of inflammation but probably as a central link between activated RAS and lipid peroxidation ([@b34]; [@b25]; [@b49]; [@b14]).

This study explains the importance of sPLA~2~-IIA as a key enzyme of inflammation-based atherosclerotic development, and a prognostic marker of cardiovascular events, based on current literature and the experimental findings of our group.

What are phospholipases (in general sPLA~2~s) good for?
=======================================================

Phospholipases are enzymes that play a crucial role in the metabolism of phospholipids. Various groups and a remarkable number of subgroups have been identified, but specific functions for only some of these phospholipases have been established in humans. Their classification is related to the site of action on the phospholipid molecules. In this context, phospholipases may act as acylhydrolases (PLAs and PLB), lysophospholipases or phosphodiesterases (PLC and PLD) ([@b79]; [@b40]). For example, phospholipases A~2~ (PLA~2~s) catalyze the sn-2 ester bonds of glycerophospholipids and, more importantly, appear to be the most influential subfamily in pro-inflammatory processes and thereby in inflammation-initiated diseases.

This subfamily can be characterized as a group of calcium-dependent lipolytic enzymes with a preserved calcium-binding loop and a His-Asp diad at the catalytic site. More then 13 groups and up to 20 different subgroups have been described so far ([@b79]; [@b40]; [@b32]). Nonsecretory PLA~2~s include the Ca^2+^-sensitive arachidonoyl-selective 85-kDa group IVα cytosolic PLA~2~ (cPLA~2~α) ([@b46]; [@b9]), paralogs of this enzyme ([@b66]), and several Ca^2+^-independent PLA~2~s (iPLA~2~s) ([@b5]).

Many cell types can secrete sPLA~2~s, especially sPLA~2~-IIA such as mesangial cells ([@b65]; [@b76]), vascular smooth muscle ([@b60]; [@b43]), endothelial cells ([@b57]), platelets ([@b24]), mast cells ([@b16]; [@b68]), neutrophils ([@b92]), macrophages ([@b28]; [@b6]; [@b89]), and hepatic cells ([@b11]).

Several pro-inflammatory stimuli may lead to secretion of diverse enzymes including phospholipases as part of a host defense mechanism. Such stimuli could be microbial pathogens as well as chemical irritants, allergens or physical stress factors. CPLA~2~α as well as the sPLA~2~s have been involved in various physiological and pathological functions such as release of pro-inflammatory mediators, cell proliferation, ischemic injury, inflammatory and allergic disease, lipid modification, cancer, and antibacterial defense ([@b9]; [@b88]; [@b73]; [@b19]). The presence of sPLA~2~-IIA activity in tears or seminal plasma, which may come into contact with bacterial pathogens, also suggests primary antibacterial properties of these enzymes. In this sense, sPLA~2~-IIA is able to destroy the membranes of Gram-positive bacteria. Interestingly, in Gram-negative bacteria sPLA~2~-IIA cannot directly attack the phospholipids of the intact cell membranes, but needs the cooperative action of neutrophils which produce bactericidal permeability-increasing protein (BPI) to support this function ([@b92]; [@b44]). Phospholipases could therefore act in the frame of combined inflammation associated humoral and cellular responses.

SPLA~2~s do not exhibit acyl chain specificity, whereas a preferential effect on arachidonic acid (AA)-containing membrane phospholipids, compared with those containing other fatty acids, could be demonstrated for cPLA~2~α. The cPLA~2~α, group IIA, and group V PLA~2~s are the primary PLA~2~s responsible for producing AA and its metabolites in endothelial, fibroblastic mast and macrophage cell lines ([@b4]; [@b69]; [@b67]). A profound cross-talk between cytosolic phospholipase A~2~ (cPLA~2~) and sPLA~2~-IIA with regard to free radical release has been confirmed by some investigations ([@b22]). Immunohistochemistry studies have further demonstrated the presence of group IIA, group V and group X secretory phospholipase A~2~ in murine and human atherosclerotic lesions ([@b59]; [@b71]; [@b91]; [@b90]).

On the other hand, it could be shown that there are changes in serum cholesterol levels with decreased concentrations of high density (HDL) and low density lipoproteins (LDL) in patients suffering from generalized infectious diseases such as sepsis. Moreover, a frequent finding in patients with persisting infections, metastatic tumors or chronic inflammatory diseases is hypocholesterolemia ([@b20]; [@b87]). The serum concentration of sPLA~2~-IIA, especially the activity of the enzyme, is markedly increased in these diseases, acting as an acute-phase-reactant ([@b12]; [@b31]; [@b54]).

In acute or chronic inflammatory states, serum levels of pro-inflammatory cytokines, such as interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ are also increased and may induce sPLA~2~-IIA ([@b64]; [@b54]; [@b1]). These pro-inflammatory cytokines can also be released at an increased rate by the liver and locally by other cells especially within the atherosclerotic plaque. Such increased PLA~2~-activity in serum is thought to lead to a more efficient clearance of lipoproteins mainly through the liver, thereby resulting in hypocholesterolemia ([@b12]; [@b31]; [@b54]; [@b32]).

Therefore, early evidence suggested the existence of a central link between systemic as well as local inflammatory processes and lipid metabolism, and that this link could be sPLA~2~-IIA.

The secretory phospholipase A~2~, group IIA role in atherogenesis
=================================================================

The key role played by sPLA~2~-IIA in the development of atherosclerosis, not merely as a mediator for localized inflammation, has been indicated by a number of recent in-vitro and in-vivo studies as follows. The enzyme seems to play an important role as an integral modulator at several stages of atherogenesis.

In the arterial wall, sPLA~2~, especially sPLA~2~-IIA, may exert proatherogenic effects in multiple steps ([@b30]). The isoenzyme sPLA~2~-IIA is located mainly in vascular smooth muscle cells of normal human arteries ([@b70]; [@b74]). In contrast, in atherosclerotic plaques the enzyme is detectable within the lipid cores, in macrophage-rich regions and in the extracellular matrices of the affected intima. Furthermore, sPLA~2~-IIA has a close spatial relationship to collagen fibres ([@b70]). As mentioned above, the expression of sPLA~2~-IIA in these cells is assumed to be up-regulated in vitro by several cytokines present in human atherosclerotic lesions, including IL-1β, TNF-α and IFN ([@b54]; [@b64]; [@b1]).

One of the first important features in atherogenesis is the retention of LDL particles in the subendothelial space. The modification of LDL mediated by sPLA~2~-IIA can change the structural organisation of the LDL particle leading to more pronounced lipid accumulation in the vessel wall. Such sPLA~2~-IIA modified LDL are characterized through an increased affinity for proteoglycans.

As a result of the hydrolytic activity, sPLA~2~-IIA releases free fatty acids and lyso-phosphatidylcholine(PC) ([@b93]; [@b2]; [@b17]; [@b30]; [@b30]). This action may affect the functions and properties of vascular endothelial and smooth muscle cells, and of macrophages, at sites of LDL accumulation ([@b81]; [@b45]). It should be noted that sPLA~2~-IIA prefers phosphatidic acid (PA) as substrate over other phospholipids found in plasma membranes including phosphatidylserine (PS), phosphatidylcholine (PC) and phosphatidylethanolamine (PE). Sintko and colleagues reported the following order of substrate preference: PA \> PE approximately PS \> PC ([@b80]).

The ability of sPLA~2~-IIA to hydrolyze PC seems to be weak, but several conditions may amplify that function. sPLA~2~-IIA acts on oxidized (ox-)LDL more efficiently by transforming LDL to a more atherogenic form. This action is based on the fact that oxidative modification of phospholipids increases their sPLA~2~-IIA susceptibility ([@b15]). Furthermore, the closed spatial contact of sPLA~2~-IIA with matrix proteoglycans (in general decorin, biglycan and versican) may increase the hydrolytic activity of sPLA~2~-IIA toward PC in LDL ([@b75]).

Moreover, sPLA~2~-IIA modified proteoglycan-bound lipoproteins show a greater tendency to aggregation and fusion. The result is a progressive deposition of lipids within the extracellular matrices of the arterial intima ([@b21]). In addition to enhancing the retention of LDL particles in the vessel wall, there is also evidence that sPLA~2~ modification may promote macrophage LDL uptake, leading to foam cell formation ([@b26]; [@b3]).

It should be noted that other sPLA isoenzymes detectable in circulation and human atherosclerotic lesions, especially of group V and group X, have more potent actions on lipoproteins compared with sPLA~2~-IIA ([@b7]; [@b23]; [@b18]). Obviously, the sole potency of sPLA~2~-IIA in hydrolyzing the primary substrates phosphatidylethanolamine and phosphatidylserine may not be the only important feature in atherosclerotic plaque perpetuation, especially in transforming LDL into more atherogenic forms. Interestingly, sPLA~2~-V has a preferential action in hydrolysis of HDL compared with LDL, as reviewed by [@b58]. Similar to sPLA~2~-V, sPLA~2~-X definitely shows more pronounced PC-hydrolysing activity. On the other hand, sPLA~2~-X modified LDL particles have a lower tendency to aggregate ([@b23]; [@b58]). Nevertheless, we can suppose that sPLA~2~ isoenzymes may act synergistically under certain conditions ([@b77]).

Together, HDL and apolipoprotein A-I(apoA-I) are positive prognostic factors in preventing perpetuation of arteriosclerotic plaque formation; there is increasing evidence that sPLA~2~-IIA may transform these particles to pro-atherogenic and pro-inflammatory reactants. As shown by de Beer and colleagues, sPLA~2~-IIA dependent hydrolysis of HDL results in a more efficient scavenger receptor class B type I cholesteryl ester uptake, leading to an accelerated HDL catabolism in the kidney during inflammatory states ([@b13]). Moreover, HDL- and ApoA-I-catabolism as well as HDL-cholesteryl ester tissue uptake were significantly enhanced under conditions of sPLA~2~-IIA overexpression even in the absence of inflammatory preconditions ([@b85]).

The above mentioned effects promoted by sPLA~2~-IIA -- in general the release of AA -- are primarily based on increased enzyme activity. However, the noteworthy non-enzymatic properties of sPLA~2~-IIA can also contribute to atherogenesis. In this way, catalytic inactive sPLA~2~-IIA was shown to promote COX-2 expression in mast cells ([@b82]). Further effects may be mediated by the sPLA~2~ M-type receptor on smooth muscle cells independent of enzyme activity ([@b78]) and by activating signaling pathways such as ERK ([@b22]) MAP kinases or protein kinase C ([@b27]). Further research is needed to make clear whether these effects are present in atherosclerotic lesions, and how far they may contribute to atherogenesis.

sPLA~2~-IIA as a prognostic marker in coronary artery disease
=============================================================

In a similar way to chronic inflammatory diseases, plasma levels of sPLA~2~-IIA were shown to be elevated in patients with coronary artery disease (CAD) and to predict coronary events in asymptomatic patients or patients with stable angina ([@b41]). Moreover, increased plasma levels of sPLA~2~ in stable patients undergoing percutaneous coronary angioplasty (PCI) also provide independent prognostic information over other classic cardiovascular risk factors and clinical covariables ([@b47]). The prognostic value of sPLA~2~-IIA in patients with acute coronary syndromes (ACS) was first described in a study of patients with unstable angina by [@b42]. Increased plasma levels of sPLA~2~-IIA predicted recurrent coronary events, mainly revascularization procedures, independently of other established risk factors ([@b42]). [@b51] also evaluated the prognostic importance of plasma sPLA~2~-IIA levels and enzyme activity across the entire spectrum of ACS by recruiting patients from the Global Registry of Acute Coronary Events (GRACE). In this impressive study, they showed that plasma sPLA~2~ activity, in contrast to CRP or IL-18, was a major independent predictor of death and new or recurrent myocardial infarction (MI) in patients with ACS. Interestingly, total sPLA~2~-activity had a better prognostic value than the sPLA~2~-IIA antigen level.

However the study's most important finding was the fact that a single determination of sPLA~2~-activity, obtained during the two days after the onset of ischemic symptoms, provides powerful prognostic information in patients with ACS. The association between sPLA~2~ activity and the risk of subsequent death or MI was independent of the other known predictors of major adverse outcomes in patients with ACS, including the presence or absence of a history of MI or signs of heart failure at admission ([@b50]).

Additional evidence to confirm the importance of catalytic activity, as well as an elevated sPLA~2~-IIA antigen level, was gathered by [@b38]. They demonstrated that sPLA~2~-IIA is involved in the development of restenosis after PTCA in human coronary arteries and in the generation of atherogenic LDL ([@b38]).

Interestingly, sPLA~2~-IIA also seems to play an important role in predicting risk for coronary artery disease and adverse coronary events in healthy subjects, especially when combined with other pro-inflammatory risk factors like CRP ([@b8]; [@b51]).

Thus sPLA~2~-IIA can be shown to be not only a mediator for localized inflammation but also a powerful independent predictor of adverse outcomes in patients with stable CAD, or in acute coronary syndromes.

Angiotensin, LDL-peroxidation, and atherogenesis
================================================

Early evidence of a potential role for angiotensin (Ang) II in LDL oxidation was gathered by [@b35] who reported that the LDL of hypertensive patients was more responsive to oxidative modification than the LDL of normotensive subjects. Meanwhile, various interactions between Ang II and oxLDL have been demonstrated especially by the Keidar group. For example, Ang-II injection into apolipoprotein E-deficient (E~0~) mice led to increased cellular oxLDL uptake by their peritoneal macrophages (MPMs) via proteoglycan macrophage stimulation pathway, a process mediated by Il-6 ([@b33], [@b37]). In human coronary endothelial cells, Ang-II enhanced the oxLDL-uptake by up-regulating the lectin-like receptor for oxLDL (LOX-1). This effect could be blocked by the angiotensin receptor blockers (ARBs) Losartan and Candesartan ([@b52], [@b53]). Ang-II increased the cellular lipid peroxidation of MPMs by 50%--100%. Moreover, Ang-II enhanced scavenger receptor affinity to oxLDL on macrophages ([@b35]).

The effects of Ang-II are predominantly mediated via activation of the AT~1~-receptor which is coupled through guanine nucleotide binding proteins (G-proteins), adenylate cyclase and cyclic adenosine monophosphate (cAMP) as second messenger, as well as phospholipases A~2~, C and D and their products, arachidonic acid (AA), inositol triphosphate (IP3), or diacylglycerol (DG).

The mechanism of Ang-II-mediated cellular lipid peroxidation involved Ang-II binding to its cellular receptor underlined by the fact that preincubation of the cells with the Ang-II antagonist, saralasin, completely inhibited this effect. Inhibitors of phospholipase A~2~, C and D also substantially reduced Ang-II-induced macrophage lipid peroxidation ([@b33]).

Interestingly, AT~1~-receptor blockade with Losartan inhibited LDL oxidation and macrophage cholesterol biosynthesis ([@b36]), and attenuated atherosclerosis in E~0~ mice ([@b34]). In a trial by [@b25], losartan therapy for a period of 4 weeks did not significantly affect the degradation of native LDL monocyte-derived macrophages (HMDM) derived from patients. However, Losartan therapy significantly reduced HMDM uptake of oxLDL as shown by a 78% reduction in oxLDL cell-association and a 21% reduction in oxLDL degradation ([@b25]), a finding which has been also confirmed for other ARBs ([@b52], [@b53]).

All these findings suggested an integral link between angiotensin II (Ang-II) and its receptor mediated effects, and activation of pro-inflammatory and pro-atherogenic pathways which could further promote lipid peroxidation.

sPLA~2~-IIA, the possible link between activated RAS, inflammation, and lipidperoxidation: a target for treatment?
==================================================================================================================

As mentioned above, angiotensin II type 1 (AT~1~)-receptor blockade may reduce LDL-modification and atherosclerotic plaque formation in animal models of atherosclerosis. Furthermore, [@b10] demonstrated that AT~1~-mediated atherogenesis is dependent on AT~1~ expression in the vessel wall, and that the presence of this receptor in resident tissues is required to initiate AngII-induced atherosclerosis. Because of increasing evidence for involvement of sPLA~2~-IIA in modifying LDL, our group assessed whether ANG II, via its AT~1~-receptor, enhances sPLA~2~-IIA-dependent lipid peroxidation in vitro and in patients with CAD. Therefore, rat aortic smooth muscle cells were stimulated with ANG II. This stimulation resulted in enhanced sPLA~2~-IIA protein expression and sPLA~2~-IIA activity. LDL-peroxidation was consequently enhanced by ANG II. Interestingly, all these effects could be reduced by AT~1~-receptor blockade with losartan. Furthermore, ANG II-induced sPLA~2~ activity and LDL-peroxidation were prevented by the sPLA~2~-IIA activity inhibitor LY311727 ([@b49]).

These findings suggested that sPLA~2~-IIA activation could be the supposed link between activated RAS and lipidperoxidation, and that ANG II may elicit pro-atherosclerotic effects via sPLA~2~-IIA-dependent LDL-modification.

In order to evaluate potential clinical implications of these findings, a small number of patients with angiographically documented CAD were treated with the AT~1~-receptor blocker irbesartan (300 mg/d) for 12 weeks. Blood samples were obtained from patients pre- and post-treatment and from healthy volunteers. SPLA~2~-IIA serum level and activity, circulating antibodies against oxidized LDL (oxLDL) and oxLDL, were determined in patients and found to be significantly increased compared to healthy volunteers. Irbesartan therapy reduced these markers of inflammation, whereas total cholesterol, HDL- and LDL-fractions remained unchanged ([@b49]).

Based on these findings we investigated further the potential effect of a combined treatment with pravastatin and irbesartan on oxLDL and sPLA~2~-IIA in a group of patients with CAD. We postulated that the addition of an AT~1~-receptor antagonist to the standard secondary prevention therapy with a statin might exert additional effects on LDL oxidation and sPLA~2~-IIA. We demonstrated that both treatment regimens comparably influenced LDL-cholesterol levels. However, sPLA~2~ activity was reduced only in patients treated with the adjunction of pravastatin and irbesartan. Consequently, only the combined treatment resulted in a significant reduction of ox-LDL levels independent of changes in LDL cholesterol (Divchev et al pers comm).

All these findings suggest a possible role for AT~1~-receptor blockade in reducing LDL-peroxidation. Whether these effects can reduce the perpetuation of atherosclerosis and especially adverse cardiovascular events in patient with CAD remains to be elucidated in further studies.

Conclusion
==========

In conclusion, secretory phospholipases A~2~ (in general sPLA~2~-IIA) were shown to play an important role in atherogenesis. Furthermore, the activity of sPLA~2~-IIA is a powerful independent predictor of adverse events in stable patients with CAD and in ACS. Focusing on recent data, expression and activation of sPLA~2~-IIA in atherosclerotic lesions seemed to be one of the links between activated RAS, inflammation and the processes of lipid accumulation and lipid peroxidation in the vessel wall as main features of atherosclerosis. Therefore, direct inhibition of sPLA~2~-IIA through specific antagonists, or indirectly through AT~1~-receptor blockade, might be a new therapeutic option used to intervene in this detrimental process of plaque development. The confirmation of these therapeutic effects and their relevance in human atherosclerosis remain the foremost challenges.
